Proto Labs Form 4 shows equity awards to Chief Technology & AI Officer

Rhea-AI Filing Summary

Proto Labs, Inc. (PRLB) reported an insider equity award for its Chief Technology & AI Officer on a Form 4. On 11/17/2025, the officer received 3,718 shares of common stock as a restricted stock unit grant at a price of $0, increasing direct beneficial ownership to 3,718 shares. The filing also reports a grant of an employee stock option for 6,818 shares of common stock with a $47.07 exercise price, expiring on 11/17/2035.

The restricted stock units vest annually over four years starting on November 15, 2026, and the stock option vests on the same schedule. This structure is designed so that the officer earns the awards gradually over time, which can help align long-term incentives with company performance and retention.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Kermisch Marc

Role Chief Technology & AI Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	6,818	$0.00	--
Grant/Award	Common Stock	3,718	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 6,818 shares (Direct); Common Stock — 3,718 shares (Direct)

Footnotes (1)

1. Restricted stock units that vest annually over four years commencing on November 15, 2026. Stock option vests annually over four years commencing on November 15, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kermisch Marc

(Last) (First) (Middle)

5540 PIONEER CREEK

(Street)

MAPLE PLAIN MN 55359

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Proto Labs Inc [ PRLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology & AI Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		A		3,718(1)	A	$0	3,718	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$47.07	11/17/2025		A		6,818		(2)	11/17/2035	Common Stock	6,818	$0	6,818	D

Explanation of Responses:

1. Restricted stock units that vest annually over four years commencing on November 15, 2026.

2. Stock option vests annually over four years commencing on November 15, 2026.

Remarks:

	/s/ Kareem S. Tawfic, Attorney-in-Fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Proto Labs (PRLB) report in this Form 4?

Proto Labs reported that its Chief Technology & AI Officer received 3,718 restricted stock units of common stock and a stock option for 6,818 shares on 11/17/2025.

What are the terms of the new stock option granted by Proto Labs (PRLB)?

The employee stock option covers 6,818 shares of Proto Labs common stock at an exercise price of $47.07 per share and expires on 11/17/2035.

How do the restricted stock units for Proto Labs (PRLB) executive vest?

The 3,718 restricted stock units vest annually over four years, beginning on November 15, 2026.

How do the Proto Labs (PRLB) stock options for the Chief Technology & AI Officer vest?

The stock option for 6,818 shares vests annually over four years, with vesting commencing on November 15, 2026.

What is the officer’s ownership status after the reported Proto Labs (PRLB) transaction?

Following the reported grant, the officer beneficially owns 3,718 shares of Proto Labs common stock directly.

Was any cash paid for the restricted stock units in the Proto Labs (PRLB) Form 4?

The 3,718 restricted stock units of common stock were reported at a price of $0, indicating they were granted as equity compensation rather than purchased.